Peginterferon beta-1a

Summary

Peginterferon beta-1a is a PEGylated form of interferon beta-1a used for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. The PEGylation extends the half-life compared to non-PEGylated interferon beta-1a, allowing for less frequent dosing (every two weeks subcutaneously). It is marketed as Plegridy by Biogen.

Mechanism of Action

Peginterferon beta-1a binds to the type I interferon receptor (IFNAR1/IFNAR2) on cell surfaces, activating the JAK-STAT signaling pathway, which leads to upregulation of interferon-stimulated genes. This results in immunomodulatory effects including reduction of pro-inflammatory cytokines, inhibition of T-cell activation and trafficking across the blood-brain barrier, and modulation of B-cell activity, thereby reducing inflammation and demyelination in multiple sclerosis.

Routes of Administration

Goals & Uses

• Reduce relapse rate in relapsing-remitting multiple sclerosisDisease ModificationHigh
• Active secondary progressive MS managementDisease ModificationModerate
• Treatment of clinically isolated syndrome (CIS)Disease ModificationModerate
• Reduce MRI lesion burden in MSDisease ModificationHigh
• Delay disability progression in MSDisease ModificationModerate

Contraindications

• Decompensated hepatic diseaseHepaticHigh
• Known hypersensitivity to natural or recombinant interferon beta, peginterferon, or any excipientAllergy/ImmunologyHigh

Adverse Effects

• Flu-like symptomsSystemic/ImmunologicalCommon
• Injection site reactionsLocalCommon
• Elevated liver enzymes (hepatotoxicity)HepaticUncommon
• Anaphylaxis and serious allergic reactionsImmunologicRare
• Depression and suicidal ideationPsychiatricUncommon
• Leukopenia/lymphopeniaHematologicUncommon

Drug Interactions

• Live attenuated vaccinesModerate
• Myelosuppressive agentsModerate
• CYP450 substrates (narrow therapeutic index)Low
• Hepatotoxic drugsModerate

Population Constraints

• Pre-existing psychiatric disordersPsychiatricRelative
• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Severe renal impairmentOrgan ImpairmentRelative
• Pediatric patients (<18 years)AgeRelative

Regulatory Status

• European UnionApprovedApproved: Relapsing-remitting multiple sclerosis in adultsEMA approved July 2014; marketed as Plegridy by Biogen in the European Union.
• United StatesApprovedApproved: Relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MSFDA approved August 2014; available as Plegridy (Biogen). Label updated to broaden relapsing MS indications.
• United KingdomApprovedApproved: Relapsing-remitting multiple sclerosis in adultsApproved by MHRA; available as Plegridy post-Brexit under UK authorization.

Approved by the FDA in August 2014 and by the EMA in July 2014 for relapsing forms of multiple sclerosis. FDA label updated to include clinically isolated syndrome and active secondary progressive MS.

Evidence & Sources

No sources recorded yet.